Several clinical trials have shown beneficial effects of sodium–glucose co-transporter 2 (SGLT2) inhibitors on kidney disease progression and cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD) with and without type 2 diabetes mellitus. This evidence concerns the gene SLC5A2 and kidney disorder.